<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00769223</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000597000</org_study_id>
    <secondary_id>UCSF-H7056-08989</secondary_id>
    <secondary_id>NCI-2019-08819</secondary_id>
    <secondary_id>01558</secondary_id>
    <nct_id>NCT00769223</nct_id>
  </id_info>
  <brief_title>Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer</brief_title>
  <official_title>Pre-Operative Gleason Score and PSA and Clinical Stage in Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Gathering information about the Gleason score, prostate-specific antigen (PSA)&#xD;
      level, and cancer stage from patients who have undergone radiation therapy for prostate&#xD;
      cancer may help doctors predict how patients respond to treatment and help plan the best&#xD;
      treatment.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying the Gleason score, PSA level, and cancer stage in&#xD;
      predicting outcome in patients who have undergone radiation therapy for localized prostate&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the value of the pre-operative Gleason score, prostate-specific antigen level,&#xD;
           and clinical stage in predicting the risk of failure and death in patients who have&#xD;
           undergone radiotherapy for localized prostate cancer.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patient medical records are reviewed to collect data about pre-treatment prostate biopsy,&#xD;
      assigned Gleason score, prostate-specific antigen level, and radionucleotide bone scan.&#xD;
&#xD;
      Patients complete a Bowel Toxicity questionnaire to assess quality of life related to acute&#xD;
      and long-term bowel toxicity after radiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 25, 1993</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Value of the pre-operative Gleason score, prostate-specific antigen level, and clinical stage in predicting the risk of failure and death</measure>
    <time_frame>Up to 30 years or until death</time_frame>
    <description>The investigator will be analyzing the effect of baseline patient and clinical features such as age, Gleason score, PSA, clinical stage and percent positive biopsies on survival as well as quality of life parameters including potency, continence, and American Urological Association (AUA) symptoms scores</description>
  </primary_outcome>
  <enrollment type="Actual">3561</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Radiation Toxicity</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical chart review</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Prostate Cancer patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of localized adenocarcinoma of the prostate&#xD;
&#xD;
          -  Has undergone radiotherapy (external beam radiotherapy and/or brachytherapy) with or&#xD;
             without hormonal therapy for adenocarcinoma of the prostate in the University of&#xD;
             California, San Francisco (UCSF) Radiation Oncology Department at San Francisco&#xD;
             General Hospital or Veterans Administration Medical Center of San Francisco between&#xD;
             1987 and 2006&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mack Roach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 8, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2008</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiation toxicity</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

